Marker Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Marker Therapeutics
MRKR Stock  USD 1.27  0.01  0.78%   
Marker Therapeutics financial statements provide useful quarterly and yearly information to potential Marker Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Marker Therapeutics financial statements helps investors assess Marker Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Marker Therapeutics' valuation are summarized below:
Gross Profit
-5.6 M
Profit Margin
(1.80)
Market Capitalization
13.7 M
Enterprise Value Revenue
3.4122
Revenue
5.4 M
There are over one hundred nineteen available fundamental ratios for Marker Therapeutics, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to check Marker Therapeutics' last-minute fundamental performance against the performance between 2010 and 2025 to make sure the trends are evolving in the right direction. As of 03/19/2025, Market Cap is likely to grow to about 39.2 M. Also, Enterprise Value is likely to grow to about 27.1 M

Marker Therapeutics Total Revenue

4 Million

Check Marker Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Marker Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.6 M, Interest Expense of 12.9 K or Selling General Administrative of 5.6 M, as well as many indicators such as Price To Sales Ratio of 15.99, Dividend Yield of 0.0 or PTB Ratio of 3.26. Marker financial statements analysis is a perfect complement when working with Marker Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Marker Therapeutics Correlation against competitors.
To learn how to invest in Marker Stock, please use our How to Invest in Marker Therapeutics guide.

Marker Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets13.6 M19.7 M20.5 M
Slightly volatile
Short and Long Term Debt Total9.2 M8.8 M4 M
Slightly volatile
Other Current Liabilities2.5 M2.2 M3.3 M
Very volatile
Total Current Liabilities4.6 M3.5 M5.9 M
Very volatile
Property Plant And Equipment Net21.5 M20.5 M7.7 M
Slightly volatile
Accounts Payable1.3 M1.1 M1.4 M
Slightly volatile
Cash9.6 M17.4 M15.2 M
Slightly volatile
Cash And Short Term Investments9.6 M17.4 M15.2 M
Slightly volatile
Net Receivables1.2 M1.2 M473.8 K
Slightly volatile
Common Stock Total Equity41.4 K58.3 K49.4 K
Very volatile
Common Stock Shares Outstanding10.6 M10.1 M3.7 M
Slightly volatile
Liabilities And Stockholders Equity13.6 M19.7 M20.5 M
Slightly volatile
Other Current Assets2.4 M2.3 M1.1 M
Slightly volatile
Other Stockholder Equity543.8 M517.9 M260.3 M
Slightly volatile
Total Liabilities6 M3.5 M7.9 M
Pretty Stable
Property Plant And Equipment Gross21.5 M20.5 M7.9 M
Slightly volatile
Total Current Assets10.3 M19.7 M16.4 M
Slightly volatile
Short Term Debt714.4 K663.8 K691.7 K
Pretty Stable
Common Stock9.7 K10.2 K41.2 K
Slightly volatile
Property Plant Equipment26.7 M25.5 M8 M
Slightly volatile
Current Deferred Revenue3 M2.9 M1.4 M
Slightly volatile
Capital Surpluse230.6 M441.1 M227.4 M
Slightly volatile
Short and Long Term Debt4.3 K4.5 K22.9 K
Slightly volatile
Net Invested Capital24.2 M12.6 M17.2 M
Slightly volatile
Net Working Capital20.6 M12.6 M14.9 M
Slightly volatile
Capital Stock7.6 K8 K38.8 K
Slightly volatile
Capital Lease Obligations8.9 M8.8 M3.9 M
Slightly volatile
Non Current Liabilities Other14.3 M13.6 M4.9 M
Slightly volatile

Marker Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative5.6 M8.6 M7.5 M
Slightly volatile
Other Operating Expenses16.1 M20.6 M23.5 M
Slightly volatile
Research Development10.9 M12 M16 M
Pretty Stable
Total Operating Expenses15.6 M8.6 M22.1 M
Pretty Stable
Non Recurring140.1 M133.5 M75.1 M
Slightly volatile
Interest Income291.5 K402.5 K306.9 K
Pretty Stable
Reconciled Depreciation2.3 M4.2 M1.3 M
Slightly volatile

Marker Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow9.3 M13.5 M14.1 M
Slightly volatile
Depreciation4.4 M4.2 M1.4 M
Slightly volatile
Total Cash From Financing Activities1.2 M1.3 M10.4 M
Pretty Stable
End Period Cash Flow10 M17.4 M15.3 M
Slightly volatile
Stock Based Compensation937.7 K987 K3.3 M
Very volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio15.9916.83181
Slightly volatile
Days Sales Outstanding218130189
Very volatile
Average Payables498.9 K964.5 K949.7 K
Pretty Stable
Stock Based Compensation To Revenue0.280.315.0859
Pretty Stable
Capex To Depreciation1.641.211.9406
Very volatile
EV To Sales11.011.58134
Slightly volatile
Payables Turnover14.212.4710.8699
Pretty Stable
Sales General And Administrative To Revenue2.472.628.6776
Slightly volatile
Research And Ddevelopement To Revenue3.443.6258.8122
Very volatile
Capex To Revenue0.470.492.1788
Pretty Stable
Cash Per Share1.871.9716.9518
Slightly volatile
Days Payables Outstanding36.7938.72150
Slightly volatile
Income Quality1.111.050.7419
Slightly volatile
Current Ratio5.265.014.9485
Slightly volatile
Receivables Turnover2.752.9330
Pretty Stable
Capex Per Share0.650.681.1734
Slightly volatile
Average Receivables1.6 M1.5 M623.4 K
Slightly volatile
Revenue Per Share0.230.340.2493
Slightly volatile
Interest Debt Per Share1.01.05163
Slightly volatile
Debt To Assets0.240.254.0677
Slightly volatile
Operating Cycle74.3570.81183
Pretty Stable
Days Of Payables Outstanding36.7938.72150
Slightly volatile
Ebt Per Ebit1.30.871.7814
Pretty Stable
Quick Ratio5.575.35.0112
Slightly volatile
Net Income Per E B T0.790.90.9481
Pretty Stable
Cash Ratio4.644.424.6664
Slightly volatile
Days Of Sales Outstanding218130189
Very volatile
Free Cash Flow Operating Cash Flow Ratio0.871.071.0714
Pretty Stable
Fixed Asset Turnover0.810.581.0083
Slightly volatile
Debt Ratio0.240.254.0677
Slightly volatile
Price Sales Ratio15.9916.83181
Slightly volatile
Asset Turnover0.190.220.1227
Pretty Stable

Marker Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap39.2 M20 M39 M
Slightly volatile
Enterprise Value27.1 M16.2 M26.9 M
Slightly volatile

Marker Fundamental Market Drivers

Cash And Short Term Investments15.1 M

Marker Upcoming Events

27th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Marker Therapeutics Financial Statements

Marker Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Marker Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Marker Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Marker Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue2.9 M3 M
Total Revenue3.8 M4 M
Cost Of Revenue12 M15.1 M
Stock Based Compensation To Revenue 0.30  0.28 
Sales General And Administrative To Revenue 2.60  2.47 
Research And Ddevelopement To Revenue 3.62  3.44 
Capex To Revenue 0.49  0.47 
Revenue Per Share 0.34  0.23 
Ebit Per Revenue(3.96)(4.16)

Additional Tools for Marker Stock Analysis

When running Marker Therapeutics' price analysis, check to measure Marker Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marker Therapeutics is operating at the current time. Most of Marker Therapeutics' value examination focuses on studying past and present price action to predict the probability of Marker Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marker Therapeutics' price. Additionally, you may evaluate how the addition of Marker Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY